Company news

Rakovina Therapeutics Inc news in 2026

Rakovina Therapeutics Inc's news releases, calls and decks from 2026, newest first.

View company

Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium

November 16, 2026

Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov

November 12, 2026

Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI(TM) Platform for DNA-Damage Response Oncology Drug Discovery

November 10, 2026

Rakovina Therapeutics Announces Shares for Debt Transaction

November 5, 2026

Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting

November 5, 2026

Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

October 28, 2026

Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection

October 22, 2026

Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

October 14, 2026

Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development

October 1, 2026

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

September 17, 2026

Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

September 10, 2026

Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

August 31, 2026

Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

August 31, 2026

Rakovina Therapeutics Announces Results from 2026 Annual General Meeting

August 19, 2026

Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement

August 12, 2026

Rakovina Therapeutics Announces $1.5 Million Private Placement

July 15, 2026

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

June 1, 2026

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

April 30, 2026

Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting

April 22, 2026

Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum

March 23, 2026

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

March 12, 2026

Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

March 5, 2026

Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

February 20, 2026

Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit

February 4, 2026

Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring

January 27, 2026

Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

January 8, 2026

Decks in 2026